| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 6, 2019- Preliminary clinical data on CA-4948 demonstrates anti-cancer activity and favorable safety profile -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing...
-
Dec 6, 2019- 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its...
-
Nov 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...
-
Nov 6, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and...
-
Nov 5, 2019- Management to host conference call today at 8:30 a.m. ET -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter...
-
Oct 31, 2019
In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq...
-
Oct 4, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2019, the independent...
-
Sep 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...
-
Sep 12, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief...
-
Aug 13, 2019- Reinhard von Roemeling, M.D., Joins Company as Senior Vice President, Clinical Development -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of Reinhard von Roemeling,...